SOUTH SAN FRANCISCO, Calif., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Senti Biosciences, Inc. (Nasdaq: SNTI) ("Senti Bio"), a clinical-stage biotechnology company developing next-generation cell and gene therapies using its proprietary Gene Circuit platform, today announced that Timothy Lu, M.D., Ph.D., Co- Founder and Chief Executive Officer of Senti, has been selected to deliver an on-stage company presentation at the Healthcare Conference Taipei 2026, co-hosted by J.P. Morgan, UC Berkeley, and the Regent Taipei ...

Core Viewpoint - Hemostemix Inc. has appointed Dr. York Hsiang as a Business Consultant, aiming to enhance its operations in treating patients with severe ischemic conditions through its autologous stem cell therapy, ACP-01 [1][9]. Company Overview - Hemostemix is an autologous stem cell therapy platform company founded in 2003, recognized as a World Economic Forum Technology Pioneer. The company has developed and patented VesCell™ (ACP-01), which has shown significant clinical results in treating various cardiovascular conditions [9]. - The company has completed seven clinical studies involving 318 subjects, with results published in eleven peer-reviewed publications. ACP-01 has demonstrated safety and clinical relevance, particularly for conditions like peripheral arterial disease and chronic limb threatening ischemia [9]. Appointment of Dr. York Hsiang - Dr. Hsiang, a globally respected vascular surgeon and Professor Emeritus at the University of British Columbia, has been appointed as a Business Consultant. His extensive experience in vascular surgery and clinical epidemiology positions him to guide Hemostemix in its strategic initiatives [4][5]. - Dr. Hsiang has previously served as the Principal Investigator for Hemostemix's Phase II clinical trial of ACP-01, reinforcing his credibility in the field [4][9]. Clinical Impact of ACP-01 - ACP-01 is considered a game changer for patients with critical limb threatening ischemia (CTLI), where traditional options often lead to amputation. Dr. Hsiang emphasized that he has not seen a therapy as effective as ACP-01 in his 30 years of medical practice [3][2]. - The Phase II trial results indicated a 0% mortality rate in the studied population, with 83% of patients experiencing wound healing and cessation of pain over a follow-up period of up to 4.5 years [9]. Collaboration with First Nations - Hemostemix is actively engaging with Canada's First Nations to establish healthcare initiatives that respect Indigenous sovereignty and promote local employment and capacity-building [7][8]. - The company aims to create a collaborative business plan that integrates traditional cultural healing methodologies with clinical excellence, positioning First Nations communities as centers of healing [8][11].

Core Insights - The article discusses the investment potential of XERS, highlighting a beneficial long position in its shares by the analyst [1]. Group 1 - The analyst expresses a personal opinion on XERS without receiving compensation from the company [1]. - There is an emphasis on the uncertainty of financial predictions and projections, which are merely median estimates [2]. - The article clarifies that past performance does not guarantee future results, and no specific investment advice is provided [3].

Core Insights - Ernexa Therapeutics is advancing its lead cell therapy, ERNA-101, towards a first-in-human trial for ovarian cancer following a successful Pre-IND meeting with the FDA [2][3] - The FDA's regulatory alignment provides a clear pathway for Ernexa to submit an Investigational New Drug application and initiate clinical testing in the second half of 2026 [3] - The company is currently engaged in technology transfer for clinical-grade manufacturing, enhancing operational readiness for its synthetic, allogeneic induced mesenchymal stem cell (iMSC) therapies [3] Company Overview - Ernexa Therapeutics focuses on developing innovative cell therapies for advanced cancer and autoimmune diseases, utilizing induced pluripotent stem cells (iPSCs) to create induced mesenchymal stem cells (iMSCs) [5] - The company's lead product, ERNA-101, is designed to activate and regulate the immune system's response to cancer cells, while ERNA-201 targets inflammation for autoimmune disease treatment [6] - Ernexa's allogeneic synthetic iMSCs offer a scalable, off-the-shelf treatment solution without the need for patient-specific cell harvesting [5]

PARAMUS, NJ, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Polaryx Therapeutics (Nasdaq: PLYX), a clinical-stage biotechnology company developing novel, disease-modifying therapies for rare, pediatric lysosomal storage disorders (“LSDs”), announces it will be presenting a late-breaking abstract on new data for PLX-200, an investigational therapy for the treatment of Krabbe disease (globoid cell leukodystrophy) at the 22nd Annual WORLDSymposium™, held February 2-6, 2026 in San Diego, Calif. These data support the contin ...

Next-generation therapeutic cancer vaccines in development for various oncology indications sold to NeoTrail Therapeutics with an undisclosed purchase priceNEW YORK and VIENNA, Austria, Feb. 03, 2026 (GLOBE NEWSWIRE) -- HOOKIPA Pharma Inc. (OTCID: HOOK, “HOOKIPA”, the “Company”) today announced the sale of its immuno-oncology related assets, consisting primarily of the HB-200 (eseba-vec) and HB-700 development programs, to NeoTrail Therapeutics, Inc. (“NeoTrail”). The purchase price remains undisclosed. "We ...

Kennewick, WA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Vivos Inc. (OTCQB: RDGL) is pleased to provide shareholders with a positive update on the ongoing human therapy demonstrations in India using RadioGel® Precision Radionuclide Therapy™. Initiated in December 2024, a prominent physician in India began treating patients to demonstrate safety and measure efficacy with RadioGel®. Patients have continued to attend their scheduled regulatory follow-up visits in accordance with the protocol. To date, no reports of se ...

- Safety and clinical outcomes of Phase 1 study of VCN-01 (zabilugene almadenorepvec) in refractory retinoblastoma patients to be presented in an invited session at the 41st Asia-Pacific Academy of Ophthalmology (APAO) Congress in Hong Kong on Saturday, 07 February 2026 – - Preclinical data will highlight synergistic antitumor activity for the combination of topotecan and VCN-01 that may improve outcomes in refractory retinoblastoma patients with difficult-to-treat vitreous seeds - ROCKVILLE, Md. and BARCEL ...

April 10, 2026 Target Action Date for RP1 in Advanced MelanomaWOBURN, Mass., Feb. 03, 2026 (GLOBE NEWSWIRE) -- Replimune Group, Inc. (Nasdaq: REPL), a clinical stage biotechnology company pioneering the development of novel oncolytic immunotherapies, today announced financial results for the fiscal third quarter ended December 31, 2025 and provided a business update. The Company's Biologics License Application (BLA) resubmission for RP1 (vusolimogene oderparepvec) in anti-PD-1 failed melanoma was accepted b ...

Meeting with the FDA to review the results from the Phase 3 EFZO-FIT™ study and determine the path forward for efzofitimod in pulmonary sarcoidosis is scheduled for mid-April 2026. SAN DIEGO, Feb. 03, 2026 (GLOBE NEWSWIRE) -- aTyr Pharma, Inc. (Nasdaq: ATYR) (“aTyr” or the “Company”), a clinical stage biotechnology company engaged in the discovery and development of first-in-class medicines from its proprietary tRNA synthetase platform, today announced that the U.S. Food and Drug Administration (FDA) has ac ...